ArticleCureus2025
Fracture Risk After Corticosteroid Injections in Non-geriatric Patients With Upper Extremity Osteoarthritis: A Retrospective Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCorticosteroid injections (CSIs) are commonly used for symptomatic management of upper extremity osteoarthritis (OA). While systemic corticosteroids are associated with impaired bone health, the fracture risk of intra-articular CSIs in younger patients remains unclear. This study aimed to determine whether intra-articular CSIs of the shoulder, elbow, or wrist increase short-term fragility fracture risk in non-geriatric patients with upper extremity OA.
methodsWe retrospectively reviewed patients aged < 65 years who received intra-articular CSIs in the shoulder, elbow, or wrist between 2018 and 2023. Patients with prior upper extremity fractures, ipsilateral shoulder arthroplasty, metabolic bone disease, or medications affecting bone metabolism were excluded. Data on demographics, injection history, and fracture occurrence were collected and analyzed using chi-squared tests and logistic regression, with significance set at p < 0.05.
resultsAmong 431 patients (mean age = 45.5 ± 10.64 years; 46.4% female), the fracture incidence after CSI was 1.9% (8/431) over a mean follow-up of 390 days. Fracture risk was not significantly associated with age (p = 0.92), sex (p = 0.36), body mass index (p = 0.11), smoking status (p = 0.24), injection site (p = 0.99), or injection frequency (p = 0.533). Logistic regression confirmed no association between the number of injections and fracture occurrence (p = 0.61).
conclusionsIntra-articular CSIs of the shoulder, elbow, or wrist were not associated with an increased short-term fragility fracture risk in non-geriatric patients with upper extremity OA. These findings support the continued use of CSIs in younger populations, although long-term and higher-risk cohorts warrant further investigation for broader risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.